NCT06819657 Safety , Feasibility and Preliminary Efficacy of Remote Ischemic Conditioning in Patients With Aneurysmal Subarachnoid Hemorrhage After Aneurysm Clipping
| NCT ID | NCT06819657 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Subarachnoid Hemorrhage, Aneurysmal |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-03-10 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-03-10 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study was designed to evaluate the safety and efficacy of remote ischemic conditioning (RIC) in patients with aneurysmal subarachnoid hemorrhage (aSAH) following surgical clipping. Aneurysmal subarachnoid hemorrhage is a life-threatening condition that occurs when a cerebral aneurysm ruptures, causing bleeding into the subarachnoid space. Surgical clipping of the aneurysm is a standard procedure used to stop the bleeding and prevent re-rupture, thereby stabilizing the patient's condition. Remote ischemic conditioning (RIC) is a non-invasive treatment that involves using a blood pressure cuff to induce brief, temporary cycles of ischemia and reperfusion in a limb. Research suggests that this process may confer systemic protective effects, potentially improving recovery from brain injury or surgery. Although RIC has shown potential to improve outcomes in patients with other neurological conditions, its effect on patients with aSAH who undergo surgical clipping remains unclear. This study will evaluate whether RIC can reduce complications, improve neurological function, and enhance overall recovery in these patients. The findings will help determine whether RIC should be incorporated into the standard treatment regimen for aSAH.
Eligibility Criteria
Inclusion Criteria: 1. Imaging examination confirmed aneurysmal subarachnoid hemorrhage. 2. Responsible aneurysms received craniotomy clipping within 24 hours. 3. 18≤ age ≤80 years old. 4. Informed consent of the participant or legally authorized representative Exclusion Criteria: 1. Patients with other types of cerebral hemorrhage. 2. Prior neurological impairment (mRS Score \>1) or mental illness may confuse neurological or functional assessment. 3. Severe comorbidities with a life expectancy of less than 90 days. 4. Refractory hypertension (systolic blood pressure 180\>mmHg or diastolic blood pressure 110\>mmHg). 5. RIC contraindications: severe soft tissue injury of lower limbs. 6. Simultaneously participate in another research program to study a different experimental therapy. 7. Any condition that the investigator believes may increase the patient's risk.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06819657 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Subarachnoid Hemorrhage, Aneurysmal. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06819657 currently recruiting?
Yes, NCT06819657 is actively recruiting participants. Contact the research team at liuaihuadoctor@ccmu.edu.cn for enrollment information.
Where is the NCT06819657 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06819657 clinical trial?
NCT06819657 is sponsored by Beijing Tiantan Hospital. The trial plans to enroll 40 participants.